Clinical trials: Sirolimus, completed
Pharmacokinetics, Drug Interactions
Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects
The purpose of this study is to confirm a significant influence of ezetimibe and sirolimus on each others pharmacokinetics
- Conditions
- Pharmacokinetics, Drug Interactions, Hypercholesterolemia, Immunosuppression
- Trial name
- NCT00621101
- Testing
- 1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany, 1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany, 1 tablet Ezetrol(R) + 1 tablet Rapamune(R)
- Where
- Germany
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Bioavailability Study
NPC-12G Gel 0.2% Sirolimus PK Bridging Study
This study is designed to describe the relative systemic bioavailability of topical and oral sirolimus formulations.
- Trial name
- NCT03972462
- Testing
- NPC-12G Gel 0.2%, Rapamune® 2 mg tablet
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Nobelpharma
Kidney Transplantation, Immunity
Protective Immunity Project 01
Patients who undergo kidney transplant must take medications to prevent organ rejection. There are standard immunosuppressant medications such as prednisone, tacrolimus (Prograf), mycophenolate mofetil(Cellcept) or sirolimus…
- Conditions
- Kidney Transplantation, Immunity, Immunosuppression
- Trial name
- PIP-01 (NCT00788021)
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Emory University
Metformin, Prediabetes
Metformin and Molecular Aging in Prediabetes
The incidence and prevalence of type 2 diabetes mellitus (T2DM) are increasing globally. The global prevalence of diabetes has nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population.
- Trial name
- NCT07302932
- Testing
- Metformin treatment, Analyzed by qPCR for T/S ratio.
- Where
- India
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Aging
Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly
The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer.
- Trial name
- NCT02874924
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Immune Thrombocytopenic Purpura
Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia
The aim of our study is to evaluate the efficacy of rapamycin with Refractory Immune Thrombocytopenic Purpura (RITP) and explore the further mechanism.
- Trial name
- ITP (NCT01672151)
- Testing
- rapamycin
- Where
- China
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Suzhou Medical College
Bioequivalence Study
Bioequivalence Study of NPC-12 (Sirolimus) Granules and Tablets
The purpose of this study is to evaluate the bioequivalece of NPC-12 granules in compare with NPC-12T tablets in Japanese healthy Adults
- Trial name
- NCT03765944
- Testing
- sirolimus
- Where
- Japan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Nobelpharma
Pure Red Cell Aplasia
Sirolimus Treatment for Refractory PRCA
Pure red cell aplasia (PRCA) is a kind of anemia characterized by severe reticulocytopenia and obvious bone marrow erythroblastic cells decreased.
- Trial name
- NCT03364764
- Testing
- Sirolimus
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bing Han
Coronary Artery Disease
Study Safety and Performance of the Biomime Stent in Patients With Single, De Novo, Non-Complex Coronary Lesions
1.) Indigenously developed and designed BioMimeTM is a predictably safe \& efficacious 3rd generation drug eluting stent (DES) with a propensity to minimize vascular injury by use of an intelligent mix of ultra-low strut…
- Trial name
- meriT-1 (NCT01507519)
- Testing
- Sirolimus Eluting Coronary Stent System (Biomime)
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Meril Life Sciences Pvt. Ltd.
Type 1 Diabetes, Hypoglycemia
hOKT3γ1 (Ala-Ala) Combined With Sirolimus and Delayed Tacrolimus in Type 1 Diabetic Islet Allograft Recipients
The collective effects of two-layer pancreas preservation, pretransplant islet culture, day -2 pretransplant immunosuppression, and induction immunosuppression with the FcR-nonbinding anti-CD3 monoclonal antibody hOKT3γ1…
- Trial name
- NCT00285194
- Testing
- Allogeneic Islets of Langerhans, hOKT3γ1 (Ala-Ala)
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Healthy
Bioavailability Study of Sirolimus Tablets 2 mg Under Fed Condition
This study is to assess the Sirolimus Tablets 2 mg of Dr. Reddy's Laboratories Limited, India and Rapamune® (Sirolimus) tablets 2 mg of Wyeth Laboratories, Philadelphia in healthy, adult,human subjects under Fed conditions.
- Trial name
- NCT02296762
- Testing
- Sirolimus
- Where
- India
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Aging, Insulin Resistance
Everolimus Aging Study
The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5 mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular hallmarks of aging in humans.
- Trial name
- EVERLAST (NCT05835999)
- Testing
- Everolimus 0.5 MG once per day, Everolimus 5 MG once per week
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Healthspan Improvement, Aging
Combination Gerotherapeutic Interventions for Healthspan Improvement
This study is a 90-day interventional, randomized, controlled pilot trial exploring multi-modal gerotherapies and their impact on longevity-related outcomes.
- Conditions
- Healthspan Improvement, Aging, Longevity
- Trial name
- NCT07475546
- Testing
- Rapamycin, Naltrexone, Metformin
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- AgelessRx
Systemic Lupus Erythematosus (SLE)
Prospective Study of Rapamycin for the Treatment of SLE
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown origin. It involves multiple organs including the joints, skin, kidneys and central nervous system.
- Trial name
- Rapamune (NCT00779194)
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- State University of New York - Upstate Medical University
Aging
The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals
This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin…
- Trial name
- NCT06550271
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- AgelessRx
Healthy
Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males
To find out if the blood level of lenalidomide can be changed when a drug that prevents p-glycoprotein (a protein naturally present in the body that helps carry substances across cell membranes that is found in many parts of the…
- Trial name
- NCT01712828
- Testing
- Lenalidomide, Quinidine, Temsirolimus
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Celgene
Cognitive Impairment, Mild, Alzheimer Disease
Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway
Evaluation of central nervous system penetration of orally administered Rapamune (RAPA) in older adults with Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD) and investigate associated safety, tolerability…
- Trial name
- CARPE_DIEM (NCT04200911)
- Testing
- Rapamune
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Hematologic Malignancies
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
If transplantation using mismatched unrelated donors or non-first-degree relatives could be performed with an acceptable toxicity profile, an important unmet need would be served.
- Trial name
- NCT01203722
- Testing
- Fludarabine, Cytoxan, Total Body Irradiation
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Idiopathic Pulmonary Fibrosis
The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects
A Phase I, Double-blind, Placebo-controlled, Single Oral Dose, Safety, Tolerability, and Pharmacokinetic Study, Incorporating an Evaluation of the Effect of Food on the Pharmacokinetics of HEC68498 in Healthy Male and Female…
- Trial name
- NCT03502902
- Testing
- HEC 68498
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Coronary Artery Disease
Cost-Effectiveness Study in the Reduction of Coronary Restenosis With Sirolimus-Eluting Stents
Since the advent of coronary stents, in-stent restenosis has proven to be the major limitation of interventional cardiology, occurring in as many as 30% of patients.
- Trial name
- GERSHWIN (NCT00627900)
- Testing
- bare metal stent, Cypher-Stent (Implantation of a sirolimus-eluting stent)
- Where
- Germany
- Volunteers
- 958 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany